Why Pfizer Stock Was so Healthy in August

In the world of big pharmaceutical companies, Pfizer (NYSE: PFE) stock has been a notable laggard over the past few years. It was something of a surprise, then, when it outperformed many of its peers by racing nearly 14% higher over the course of last month. A better-than-expected quarterly earnings report had something to do with that, as did several regulatory advancements.

The first significant stock-moving event for Pfizer that month was the release of its second-quarter earnings report on Aug. 4. Revenue for the pharmaceutical giant rose by 3% to $15 billion, while net income not under generally accepted accounting principles (non-GAAP, or adjusted) was up marginally to $4.4 billion, or $0.77 per share.

Continue reading